RxDoctor Payments Data

Shye Wortman, MD

Internal Medicine · Staten Island, NYNPI 1275584138

Payments from drug & device makers

$11,107in general payments, 2019–2025

Across 658 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • GSK$709
  • Bayer$686
  • Lilly USA, LLC$577
  • Amgen$576
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$1732%
  • Food & beverage$10,90198%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,107 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$199,969
Medicare patients
522
Services billed
2,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide213$385,023
JardianceEmpagliflozin161$232,672
FarxigaDapagliflozin Propanediol102$137,839
MounjaroTirzepatide94$115,381
EliquisApixaban72$98,408
KerendiaFinerenone71$71,889
JanuviaSitagliptin Phosphate46$69,080
LinzessLinaclotide72$59,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$51,565
TrulicityDulaglutide21$46,022
XareltoRivaroxaban26$31,932
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate12$31,702
MyrbetriqMirabegron40$31,016
VraylarCariprazine Hcl19$27,175
UbrelvyUbrogepant21$20,700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$525$385,023213 claims
Boehringer IngelheimJardiance, Synjardy$126$244,549174 claims
Lilly USA, LLCMounjaro, Trulicity$577$161,403115 claims
AstraZenecaFarxiga$1,056$137,839102 claims
AbbVieLinzess, Vraylar, Ubrelvy, Synthroid$3,173$114,473213 claims
PfizerEliquis$475$98,40872 claims
MerckJanuvia, Janumet$101$87,12260 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$709$72,704108 claims
BayerKerendia$686$71,88971 claims
Johnson & JohnsonXarelto$114$31,93226 claims
Almatica Pharma LLCLoreev Xr$232$10,54112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →